Semaglutide has not been proven safe for breastfeeding, and official guidelines recommend against using it while nursing. No large human studies have confirmed whether the drug passes into breast milk in meaningful amounts, though a small study of eight mothers found no detectable semaglutide in their milk. The picture is more nuanced than a simple yes or no, and the answer also depends on whether you’re taking the injectable or oral form.
What the FDA Labels Say
The FDA labeling for all semaglutide products acknowledges the same core problem: there are no robust human data on whether semaglutide enters breast milk, how it affects a nursing infant, or whether it changes milk production. In animal studies, semaglutide was found in the milk of lactating rats at levels 3 to 12 times lower than in the mother’s blood. That’s relatively low transfer, but the presence in animal milk raises the possibility it could also appear in human milk.
For the injectable versions (Ozempic, Wegovy), the label notes the lack of data and leaves the decision more open-ended. The oral tablet (Rybelsus) carries a stronger warning: the FDA explicitly recommends against breastfeeding while taking it. The reason comes down to an ingredient unique to the oral form, not semaglutide itself.
Why the Oral Tablet Gets a Stronger Warning
Rybelsus contains an absorption enhancer called SNAC that helps semaglutide survive the digestive tract and reach the bloodstream. In rat studies, SNAC and its breakdown products concentrated in breast milk at levels 2 to 12 times higher than in the mother’s blood. That’s the opposite pattern from semaglutide itself, which showed lower levels in milk than in blood.
The concern is specifically about newborns and young infants. Babies have lower activity of the enzyme responsible for clearing SNAC from the body, which could lead to a buildup in the infant’s system. Because of this, the FDA advises that women taking Rybelsus should not breastfeed, and notes that injectable formulations of semaglutide (which don’t contain SNAC) are available as alternatives during lactation.
What the Human Data Actually Show
Only one small study has measured semaglutide levels in human breast milk. Eight nursing mothers taking subcutaneous (injectable) semaglutide at doses between 0.25 and 1 mg weekly provided milk samples at 0, 12, and 24 hours after a dose. None of the samples contained any measurable semaglutide, with the detection threshold set at 1.7 micrograms per liter.
The researchers calculated that even if the milk had contained semaglutide right at that detection limit, the relative infant dose would have been only about 1.12% of the mother’s dose. In pharmacology, anything below 10% is generally considered low risk. On top of that, semaglutide is a peptide, meaning it would be broken down in the infant’s digestive tract before much could be absorbed. In adults, oral bioavailability of semaglutide maxes out at around 1% without the SNAC enhancer. In an infant’s gut, absorption would likely be similarly poor or lower.
This is reassuring data, but it comes from just eight women. It’s not enough to declare the drug definitively safe during breastfeeding.
What Animal Studies Found in Offspring
Animal research paints a more cautious picture. A systematic review published in Frontiers in Endocrinology found that GLP-1 receptor agonists (the drug class semaglutide belongs to) caused reduced growth in rat pups when mothers were exposed during lactation. Notably, reduced neonatal growth occurred even when the related drug liraglutide was used only during lactation, not during pregnancy, suggesting the effect came through the milk rather than from earlier fetal exposure.
Researchers initially speculated that peptide drugs like semaglutide would simply be digested in the infant’s gut and never reach the bloodstream. But the animal data suggest some systemic effect on the offspring, meaning the drug or its activity may reach the baby in ways not fully understood. This is one of the main reasons professional organizations continue to advise caution.
How Long Semaglutide Stays in Your System
If you’re planning to stop semaglutide and then breastfeed, timing matters. Both the oral and injectable forms have an elimination half-life of about one week. In practical terms, semaglutide remains in your circulation for roughly five weeks after your last dose. A standard pharmacological washout (five half-lives) means waiting at least five weeks after your final injection or tablet before the drug is essentially cleared from your body.
Injectable vs. Oral: A Key Distinction
The FDA’s own labeling creates an interesting distinction. While the oral tablet label says breastfeeding is “not recommended” and specifically flags the SNAC enhancer as the reason, the injectable label lacks that same definitive language. The FDA even notes that “alternative formulations of semaglutide can be used during lactation,” essentially pointing women toward the injectable versions if they and their provider decide semaglutide is necessary.
This doesn’t mean injectable semaglutide is officially endorsed for breastfeeding. It means the FDA considers the injectable form less concerning than the oral tablet, primarily because the SNAC accumulation risk is removed from the equation. The small human milk study showing undetectable drug levels was also done with the injectable form, adding to the more favorable data profile.
What Professional Organizations Recommend
The American College of Obstetricians and Gynecologists recommends against GLP-1 receptor agonists during both pregnancy and breastfeeding, citing limited safety data. This is a precautionary stance rather than one based on documented harm in humans. A 2023 systematic review of the evidence broadly supported this recommendation, particularly given that safer alternatives exist for both weight management and blood sugar control during the postpartum period.
For type 2 diabetes, metformin and insulin both have well-established safety profiles during breastfeeding. For weight management, the postpartum period naturally supports gradual weight loss through breastfeeding itself, which burns roughly 300 to 500 extra calories per day, along with dietary changes and physical activity. These options don’t carry the same unknowns that semaglutide does in a nursing infant.
Weighing the Decision
The current evidence sits in an uncertain middle ground. On one hand, the only human milk data available show no detectable semaglutide in breast milk from injectable use, and the calculated infant exposure would be very low even in a worst-case scenario. On the other hand, animal studies show measurable drug transfer and reduced growth in nursing offspring, and there are zero published reports measuring drug levels in human infants whose mothers took semaglutide.
If you’re currently taking semaglutide and want to breastfeed, the most straightforward path is stopping the medication and waiting about five weeks for it to clear. If you need ongoing treatment for diabetes or weight management during breastfeeding, alternatives with stronger safety records exist. If your provider determines that semaglutide is medically necessary, the injectable form carries fewer theoretical concerns than the oral tablet, largely because it avoids the SNAC enhancer that concentrates in milk.